MNOV Medicinova Forecast, Technical & Fundamental Analysis
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U... Show more
MNOV is expected to report earnings to rise 53.40% to -7 cents per share on August 14
Q2'26
Est.
$-0.08
Q1'26
Beat
by $0.03
Q4'25
Beat
by $0.06
Q3'25
Beat
by $0.01
Q2'25
Missed
by $0.03
The last earnings report on May 15 showed earnings per share of -5 cents, beating the estimate of -8 cents. With 207.14K shares outstanding, the current market capitalization sits at 64.48M.
A.I. Advisor
published General Information
General Information
a biopharmaceutical company, which develops small molecule therapeutics
A.I.dvisor indicates that over the last year, MNOV has been loosely correlated with NCEL. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if MNOV jumps, then NCEL could also see price increases.
MNOV's Stochastic Oscillator remains in overbought zone for 1 day
Expect a price pull-back in the near future.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 50-day moving average for MNOV moved below the 200-day moving average on May 28, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MNOV declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for MNOV entered a downward trend on June 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where MNOV's RSI Indicator exited the oversold zone, of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on June 17, 2026. You may want to consider a long position or call options on MNOV as a result. In of 100 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for MNOV just turned positive on June 17, 2026. Looking at past instances where MNOV's MACD turned positive, the stock continued to rise in of 52 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MNOV advanced for three days, in of 197 cases, the price rose further within the following month. The odds of a continued upward trend are .
MNOV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.636) is normal, around the industry mean (20.966). P/E Ratio (0.000) is within average values for comparable stocks, (36.007). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). MNOV has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (107.527) is also within normal values, averaging (367.026).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. MNOV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MNOV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
